Dual variable domain immunoglobulins and uses thereof

TL;DR: In this paper, the authors provide compositions and methods for treating diseases associated with expression of CD19, including methods of administering a genetically modified T cell expressing a chimeric antigen receptor (CAR) that comprises a CD19 binding domain.

TL;DR: In this paper, the diabody molecules of the present invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on different or differing antigens.

TL;DR: In this article, the anti-PD-1 antibody molecules can be used to treat, prevent and diagnose cancerous or infectious conditions and disorders, and they can be found to specifically bind to PD-1.

TL;DR: Purified hybrid antibody specifically enhanced the in vitro cytotoxicity of MTX-HSA for gp72 positive tumour cells and dual binding between tumour cell surface antigen and MTX was demonstrated.

TL;DR: In this article, the authors described binding proteins, such as antibodies directed to the IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described, including nucleotide sequences encoding, amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy-and light-chain sequences spanning the framework regions and/or complementarity determining regions.

TL;DR: In this article, anti-RAGE antibodies and their use for treatment of RAGE related diseases are discussed. But the authors do not discuss the use of these antibodies in the treatment of advanced glycation end products (RAGE).

TL;DR: Antibodies to heavy chain of human FcRn are provided which function as non-competitive inhibitors of IgG binding to FcRN as mentioned in this paper, which are useful for reducing the concentration of pathogenic IgGs in individuals and therefore used as a therapeutic tool in autoimmune and alloimmune conditions.